Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)
- ID: 586431
- August 2015
- Region: Global
- 1677 Pages
The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding of M&A deals.
Chapter 4 provides a review of the leading M&A deals since 2010. Deals are listed by headline value, signed by bigpharma and and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the M&A deal.
In addition the report includes a comprehensive listing of all M&A deals announced since 2010. Each listing is organized as an appendix by company A-Z, and industry sector. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in M&A dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about M&A alliances. SHOW LESS READ MORE >
Chapter 1 - Introduction
Chapter 2 - Trends in M&A dealmaking
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2010
2.3.1. Japanese M&A accelerates
2.3.2. Option to acquire the new acquisition?
2.3.3. Case study 1: Cephalon - Ception
2.3.4. Case study 2: HertArt Aps - Vitrolife
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.5.1. M&A as an alternative to IPO
2.6. Partnering deals with M&A component
2.6.1. Partnering as a precursor to M&A
2.6.1.a. Case study 3: Celgene - VentiRx Pharmaceuticals, Oct 2012
2.6.2. Equity as part of partnering deal
2.6.2.a. Case study 4: BioMarin - Catalyst Pharma Partners, Oct 2012
2.6.2.b. Case study 5: Pfizer - Clovis Oncology , June 2011
2.6.2.c. Case study 6: Tesaro - OPKO Health, December 2010
2.6.3. Conversion of partnership to acquisition
2.6.4. But M&A is not always the route followed
2.7. Big pharma mega mergers - are we at the end of the road?
2.7.1. Growth of Johnson & Johnson through M&A
2.7.2. Growth of Novartis through M&A
2.8. Accessing innovation through M&A
2.8.1. Big pharma acquisitions of small companies
2.8.1.a. Case study 7: Abbott - Facet Biotechnology
2.8.1.b. Case study 8: Gilead Sceinces - Pharmasset
2.8.2. Medium and small biopharma - use of M&A
2.8.2.a. Case study 9: Allergan - MAP Pharmaceuticals
2.8.2.b. Case study 10: Reckitt Benckiser - Schiff Nutrition International
2.8.3. Using M&A to build a company
2.8.3.a. Case study 11: Shire - built from M&A
2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.8.3.c. Case study 13: Novartis - from pure pharma to half generic
2.8.4. Emergence of biotech-biotech mergers
2.8.4.a. Case study 14: Merger between Biogen and Idec
2.8.4.b. Case study 15: Amgen acquisition activity
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma
Chapter 3 - Overview of M&A deal structure
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica - November 2012
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma - AkaRx - October 2007
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals - Callisto Pharmaceuticals - July 2012
Chapter 4 - Leading M&A deals
4.2. Top M&A deals by value
4.3. Top merger deals
4.4. Most active M&A dealmakers
4.5. Big pharma M&A deal activity
4.6. Big biotech M&A deal activity
Chapter 5 - Big pharma M&A deals
5.2. How to use M&A deals
5.3. Big pharma company M&A deal profiles
Chapter 6 - Big biotech M&A deals
6.2. How to use M&A deals
6.3. Big biotech company M&A deal profiles
Chapter 7 - M&A contracts directory
7.2. Company A-Z
7.3. By industry sector
The following appendices are available in a accompanying volume.
Appendix 1 - Company A-Z
Appendix 2 - By industry sector
Appendix 3 - M&A dealmaking references
Appendix 4 - Resources
Appendix 5 - Deal type definitions
Appendix 6 - Example M&A contract document
Table Of Figures:
Figure 1: Definition of merger and acquisition
Figure 2: Trends in M&A deal announcements, 2010-2015
Figure 3: M&A deals signed by various industry sectors, 2010-2015
Figure 4: Key recent M&A trends - 2010 to present
Figure 5: Recent Japanese M&A
Figure 6: Recent ‘option to acquire’ deals
Figure 7: Situations where M&A can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 9: Equity investments converting to acquisitions
Figure 10: Johnson & Johnson’s growth through M&A
Figure 11: Novartis’s growth through M&A since 2000
Figure 12: Shire’s M&A history
Figure 13: Amgen’s biotech-biotech acquisition trail
Figure 14: Private equity M&A activity, 2010-2015
Figure 15: Issues in implementing M&A agreements
Figure 16: Joint venture agreements, 2010-2015
Figure 17: Recent joint ventures in the biopharma sector
Figure 18: Future trends in M&A in biopharma
Figure 19: Components of the acquisition deal structure
Figure 20: Components of the merger deal structure
Figure 21: Top M&A deals by value since 2010
Figure 22: Top merger deals by value since 2010
Figure 23: Most active M&A dealmakers Jan 2010- April 2015
Figure 24: Big pharma - top 50 - M&A deals 2010 to mid 2015
Figure 25: Big pharma M&A deal frequency - 2010 to mid 2015
Figure 26: Big biotech - top 50 - M&A deals 2010 to mid 2015
Figure 27: Big biotech M&A deal frequency - 2010 to mid 2015
Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits:
- In-depth understanding of M&A deal trends since 2010.
- Analysis of the structure of M&A agreements with numerous real life case studies.
- Comprehensive access to over 2,500 actual M&A deals entered into by the world’s biopharma companies, together with contract documents if available.
- Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies.
- Insight into the terms included in a M&A agreement, together with real world clause examples.
- Full listing of M&A deals by company A-Z and industry sector.
- Understand the key deal terms companies have agreed in previous deals.
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies.
Janssen Research & Development
La Jolla Pharmaceutical
Merck and Co
Merck Sharpe & Dohme
Novartis Consumer Health
Procter & Gamble
Procter & Gamble Pharmaceuticals